Five Pipeline Developments to Watch in 2022

From continuing revolutionary advancements in gene therapy to the ongoing effects of the COVID-19 pandemic and the...

Read More

Making a Difference Every Day: A Focus on the Member Experience

The member experience is key for Elixir. This means more than a simple letter or access to a member portal. We...

Read More

Biosimilar Basics: Understanding the Difference Between Generics and Biosimilars

With rising drug costs, we’re all looking for ways to reduce out-of-pocket spend without sacrificing quality....

Read More

Elixir Formulary Decisions Deliver on Member Whole-Being Health

Prescription drug spend represented 13.7% of national health expenditures in 2018, totaling $500 billion, and is...

Read More

Closing One Chapter and Starting the Next: CMS' New Portal

The 2021 audit cycle is coming to a close. The Centers for Medicare and Medicaid Services (CMS) issued its last...

Read More

News on Approval of the First Interchangeable Biosimilar Insulin and More

From development of a medication for treatment-resistant HIV with a novel mechanism of action to approval of...

Read More

Changes in the Stars: The Pandemic's Impact on Star Ratings

The pandemic continues to have a profound impact on healthcare and that includes the Centers for Medicare and...

Read More

The Journey of Orphan Drugs: History, Development and Costs

Recent attention has been given to rare or orphan diseases—more specifically, to the costs associated with the drugs...

Read More

CMS is Now Requiring Drug Management Programs: What You Need to Know

America has been in the throes of an opioid epidemic since the late ‘90s, with half a million people dying of opioid...

Read More